Grew total revenue to $151.8 million and testing revenue to $146.4 million, representing 15% year-over-year growth Announces $100 million share ...

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported ...

<?xml encoding="utf-8" ?> Myriad Genetics MYGN reported third-quarter financial results on Wednesday. The transcript from the ...

Your health checkup or medical screening results stated "High PSA" or "Further examination required."When you looked it up, ...

Getting the right diagnosis isn't always easy. Some illnesses develop slowly, some have vague symptoms and many can be ...

(NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing therapies for chronic ...

Hello. Today I would like to write about cancer screenings. The reason is that I had some stomach discomfort earlier this ...

A Phase 1b/2 trial evaluates Iomab-ACT before commercial CD19 CAR T therapy; a sickle cell abstract is scheduled for Dec. 13 ...

In vitro studies, undertaken by two leading microbiology centers, confirm RHB-204's killing capability on Mycobacterium avium ...

Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today that it has been selected as a ...

Doctors have raised questions over the growing popularity of multi-ingredient supplements, prompting a closer look at the ...